• 

  The EU’s Health Technology Assessment Regulation: Implementation one year on

  2026-03-05T16:15:00+00:00

• 

  Beyond product approval: Bridging the gap between regulatory success and patient access for biosimilars

  2026-03-05T14:52:00+00:00

• 

  WMA declarations: Helsinki in the spotlight and Taipei in the background

  2026-03-04T17:31:00+00:00

• 

  Navigating Advanced Therapy Medicinal Product regulatory changes: European Medicines Agency and UK guidance updates

  2026-03-04T17:04:00+00:00

• 

  Cell therapy, gene therapy and tissue-engineered product manufacturing: Technical challenges, enablers and regulatory evolution

  2026-03-04T15:08:00+00:00

• 

  Navigating regulatory pathways for live biotherapeutics in the US and EU: Challenges and opportunities

  2026-03-04T12:15:00+00:00

• 

  New ICH M15 Guideline sets harmonised framework for MIDD

  2026-02-18T11:04:00+00:00

• 

  MHRA points to clinical trial growth and faster assessment routes

  2026-01-28T09:44:00+00:00

• 

  Demystifying complex generic products: Regulatory pathways and characterisation

  2026-01-14T09:52:00+00:00

• 

  Empowering digital innovation in CMC: A framework for regulatory readiness and confidence

  2026-01-14T09:44:00+00:00

• 

  Regulatory challenges and key considerations in the development of radiopharmaceuticals

  2026-01-14T09:41:00+00:00

• 

  Regulatory Rapporteur January 2026 – Contents

  2026-01-13T11:33:00+00:00

More pharmaceutical content